Cyxone's T20K development drug in 87 different pharmacological tests
In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.T20K has undergone extensive testing, amounting to a total of 87 different test systems. Cyxone has selected those pharmacological tests that are likely to have the greatest potential of being affected by the company's development substance. The tests suggest that T20K does not bind, or binds weakly, to the studied cellular receptors. Furthermore, the majority